Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Morrison Website

Deborah K. Morrison, Ph.D.

Selected Publications

1)  Freeman AK, Morrison DK.
Bonavida B, eds.
Mechanisms and Potential Therapies for Acquired Resistance to Inhibitors Targeting the Raf or MEK Kinases in Cancer. In: Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy.
New York: Springer Publishing Company; 2013. p. 47-68 [Book Chapter]
2)  Freeman AK, Ritt DA, Morrison DK.
The importance of Raf dimerization in cell signaling.
Small GTPases. 4, 2013.
3)  Freeman AK, Ritt DA, Morrison DK.
Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling.
Mol. Cell. 49: 751-8, 2013.
4)  Balamurugan K, Sharan S, Klarmann KD, Zhang Y, Coppola V, Summers GH, Roger T, Morrison DK, Keller JR, Sterneck E.
FBXW7a attenuates inflammatory signalling by downregulating C/EBPd and its target gene Tlr4.
Nat Commun. 4: 1662, 2013.
5)  Koveal D, Schuh-Nuhfer N, Ritt D, Page R, Morrison DK, Peti W.
A CC-SAM, for coiled coil-sterile a motif, domain targets the scaffold KSR-1 to specific sites in the plasma membrane.
Sci Signal. 5: ra94, 2012.
6)  Logue JS, Morrison DK.
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy.
Genes Dev. 26: 641-50, 2012.
7)  Sarkar TR, Sharan S, Wang J, Pawar SA, Cantwell CA, Johnson PF, Morrison DK, Wang JM, Sterneck E.
Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPδ expression and contributes to transformation of breast tumor cells.
Mol. Cell. Biol. 32: 320-32, 2012.
8)  Rouquette-Jazdanian AK, Sommers CL, Kortum RL, Morrison DK, Samelson LE.
LAT-independent Erk activation via Bam32-PLC-?1-Pak1 complexes: GTPase-independent Pak1 activation.
Mol. Cell. 48: 298-312, 2012.
9)  Morrison DK.
MAP kinase pathways.
Cold Spring Harb Perspect Biol. 4, 2012.
10)  Freeman AK, Morrison DK.
14-3-3 Proteins: diverse functions in cell proliferation and cancer progression.
Semin. Cell Dev. Biol. 22: 681-7, 2011.
11)  McKay MM, Freeman AK, Morrison DK.
Complexity in KSR function revealed by Raf inhibitor and KSR structure studies.
Small GTPases. 2: 276-281, 2011.
12)  McKay MM, Ritt DA, Morrison DK.
RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling.
Curr. Biol. 21: 563-8, 2011.
13)  Smith FD, Langeberg LK, Cellurale C, Pawson T, Morrison DK, Davis RJ, Scott JD.
AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade.
Nat. Cell Biol. 12: 1242-9, 2010.
14)  Wang J, Sarkar TR, Zhou M, Sharan S, Ritt DA, Veenstra TD, Morrison DK, Huang AM, Sterneck E.
CCAAT/enhancer binding protein delta (C/EBPdelta, CEBPD)-mediated nuclear import of FANCD2 by IPO4 augments cellular response to DNA damage.
Proc. Natl. Acad. Sci. U.S.A. 107: 16131-6, 2010.
15)  Ritt DA, Monson DM, Specht SI, Morrison DK.
Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling.
Mol. Cell. Biol. 30: 806-19, 2010.
16)  McKay MM, Morrison DK.
Proteomic analysis of scaffold proteins in the ERK cascade.
Methods Mol. Biol. 661: 323-34, 2010.
17)  Lim J, Zhou M, Veenstra TD, Morrison DK.
The CNK1 scaffold binds cytohesins and promotes insulin pathway signaling.
Genes Dev. 24: 1496-506, 2010.
18)  Dougherty MK, Ritt DA, Zhou M, Specht SI, Monson DM, Veenstra TD, Morrison DK.
KSR2 is a calcineurin substrate that promotes ERK cascade activation in response to calcium signals.
Mol. Cell. 34: 652-62, 2009.
19)  Costanzo-Garvey DL, Pfluger PT, Dougherty MK, Stock JL, Boehm M, Chaika O, Fernandez MR, Fisher K, Kortum RL, Hong EG, Jun JY, Ko HJ, Schreiner A, Volle DJ, Treece T, Swift AL, Winer M, Chen D, Wu M, Leon LR, Shaw AS, McNeish J, Kim JK, Morrison DK, Tschöp MH, Lewis RE.
KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity.
Cell Metab. 10: 366-78, 2009.
20)  McKay MM, Ritt DA, Morrison DK.
Signaling dynamics of the KSR1 scaffold complex.
Proc. Natl. Acad. Sci. U.S.A. 106: 11022-7, 2009.
21)  Morrison DK.
The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development.
Trends Cell Biol. 19: 16-23, 2009.
22)  McKay MM, Morrison DK.
Caspase-dependent Cleavage Disrupts the ERK Cascade Scaffolding Function of KSR1.
J. Biol. Chem. 282: 26225-34, 2007.
23)  Ritt DA, Zhou M, Conrads TP, Veenstra TD, Copeland TD, Morrison DK.
CK2 Is a component of the KSR1 scaffold complex that contributes to Raf kinase activation.
Curr. Biol. 17: 179-84, 2007.
24)  McKay MM, Morrison DK.
Integrating signals from RTKs to ERK/MAPK.
Oncogene. 26: 3113-21, 2007.
25)  Morrison D, Daar I.
Der C, eds.
Ras and the Raf-MEK-ERK Cascade. In: Ras GTPases.
Norwell: Kluwer Academic Publishers; 2006. In Press. [Book Chapter]
26)  Shalin SC, Hernandez CM, Dougherty MK, Morrison DK, Sweatt JD.
Kinase suppressor of Ras1 compartmentalizes hippocampal signal transduction and subserves synaptic plasticity and memory formation.
Neuron. 50: 765-79, 2006.
27)  Weber HO, Ludwig RL, Morrison D, Kotlyarov A, Gaestel M, Vousden KH.
HDM2 phosphorylation by MAPKAP kinase 2.
Oncogene. 24: 1965-72, 2005.
28)  Ritt DA, Daar IO, Morrison DK.
KSR Regulation of the Raf-MEK-ERK Cascade.
Meth. Enzymol. 407: 224-37, 2005.
29)  Dougherty MK, Müller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, Conrads TP, Veenstra TD, Lu KP, Morrison DK.
Regulation of Raf-1 by direct feedback phosphorylation.
Mol Cell. 17: 215-24, 2005.
30)  Morrison DK.
Cancer: enzymes play molecular tag.
Nature. 428: 813-5, 2004.
31)  Murakami MS, Moody SA, Daar IO, Morrison DK.
Morphogenesis during Xenopus gastrulation requires Wee1-mediated inhibition of cell proliferation.
Development. 131: 571-80, 2004.
32)  Ory S, Morrison DK.
Signal transduction: implications for Ras-dependent ERK signaling.
Curr Biol. 14: R277-8, 2004.
33)  Dougherty MK, Morrison DK.
Unlocking the code of 14-3-3.
J Cell Sci. 117: 1875-84, 2004.
34)  Haughn L, Hawley RG, Morrison DK, von Boehmer H, Hockenbery DM.
BCL-2 and BCL-XL restrict lineage choice during hematopoietic differentiation.
J Biol Chem. 278: 25158-65, 2003.
35)  Lochhead PA, Sibbet G, Kinstrie R, Cleghon T, Rylatt M, Morrison DK, Cleghon V.
dDYRK2: a novel dual-specificity tyrosine-phosphorylation-regulated kinase in Drosophila.
Biochem J. 374: 381-91, 2003.
36)  Müller J, Ritt DA, Copeland TD, Morrison DK.
Functional analysis of C-TAK1 substrate binding and identification of PKP2 as a new C-TAK1 substrate.
EMBO J. 22: 4431-42, 2003.
37)  Coon M, Ball A, Pound J, Ap S, Hollenback D, White T, Tulinsky J, Bonham L, Morrison DK, Finney R, Singer JW.
Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells.
Mol Cancer Ther. 2: 1067-78, 2003.
38)  Janssen RA, Kim PN, Mier JW, Morrison DK.
Overexpression of kinase suppressor of Ras upregulates the high-molecular-weight tropomyosin isoforms in ras-transformed NIH 3T3 fibroblasts.
Mol Cell Biol. 23: 1786-97, 2003.
39)  Ory S, Zhou M, Conrads TP, Veenstra TD, Morrison DK.
Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites.
Curr Biol. 13: 1356-64, 2003.
40)  Morrison DK, Davis RJ.
Regulation of MAP kinase signaling modules by scaffold proteins in mammals.
Annu Rev Cell Dev Biol. 19: 91-118, 2003.
Click Here to View Collapsed Bibliography.

This page was last updated on 9/9/2013.